Man Group’s Tango Therapeutics TNGX Stock Holding History

Man Group’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-83,473	Closed	-$277K	–	2149
2023 Q2	$277K	Buy	+83,473	New	+$300K	﹤0.01%	1743

Other funds holding TNGX

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Man Group's TNGX Position: Q3 2023 in Review

Man Group sold out of Tango Therapeutics (TNGX) in Q3 2023, closing a stake of 83,473 shares — an estimated $277K sold.

Man Group first reported a position in TNGX in Q2 2023 and held it in 1 quarter. The position peaked at $277K in Q2 2023. 100 funds tracked by Wall St. Rank hold TNGX as of Q3 2023.

Man Group reported no remaining Tango Therapeutics position as of Q3 2023 after selling out during the quarter.
Man Group sold 83,473 Tango Therapeutics shares in Q3 2023, an estimated $277K.
Man Group first reported a position in Tango Therapeutics in Q2 2023 and held it in 1 quarter.
Man Group's Tango Therapeutics position peaked at $277K in Q2 2023.
100 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.